How to use the speech recognition tool?

NCT02521311

RECOVER

This trial does use Clemastine fumarat as a remyelinating agent targeting the
muscarinic receptor on oligodendrocytes around the optic nerve.

Type: Interventional



Status of the trial: Active, Recruiting

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 0000-00-00
  • Closing Date: 2022-08-31

Criteria

Inclusion: Patients with acute optic neuritis including the rare forms, inclusion within 2 weeks after onset of ION, RION, CRION, etc

Exclusion: Major ophthalmological disease, myopia >7dpt, simultaneous bilateral ON, pregnancy, other study involvement, (please see protocol for full list)

More information

Children: No

Adults: Yes

Funder Type: other

HCP: Principal investigators

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Neuro-Ophthalmology Rare Diseases (WG2)
  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: